Literature DB >> 9059610

Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents.

L Sreerama1, N E Sladek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9059610     DOI： 10.1007/978-1-4615-5871-2_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  12 in total

1.  Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.

Authors:  Robert A Parise; Bean N Anyang; Julie L Eiseman; Merrill J Egorin; Joseph M Covey; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2012-10-05       Impact factor: 3.333

2.  Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer.

Authors:  Jing Xu; Susan Müller; Sreenivas Nannapaneni; Lin Pan; Yuxiang Wang; Xianghong Peng; Dongsheng Wang; Mourad Tighiouart; Zhengjia Chen; Nabil F Saba; Jonathan J Beitler; Dong M Shin; Zhuo Georgia Chen
Journal:  Eur J Cancer       Date:  2012-02-15       Impact factor: 9.162

3.  Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.

Authors:  Feng Jiang; Qi Qiu; Abha Khanna; Nevins W Todd; Janaki Deepak; Lingxiao Xing; Huijun Wang; Zhenqiu Liu; Yun Su; Sanford A Stass; Ruth L Katz
Journal:  Mol Cancer Res       Date:  2009-03-10       Impact factor: 5.852

Review 4.  Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily.

Authors:  Satori A Marchitti; Chad Brocker; Dimitrios Stagos; Vasilis Vasiliou
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-06       Impact factor: 4.481

5.  Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study.

Authors:  Masaharu Nomura; Tetsuya Fukuda; Kiyonaga Fujii; Takeshi Kawamura; Hiromasa Tojo; Makoto Kihara; Yasuhiko Bando; Adi F Gazdar; Masahiro Tsuboi; Hisashi Oshiro; Toshitaka Nagao; Tatsuo Ohira; Norihiko Ikeda; Noriko Gotoh; Harubumi Kato; Gyorgy Marko-Varga; Toshihide Nishimura
Journal:  J Clin Bioinforma       Date:  2011-09-03

6.  4-(N,N-dipropylamino)benzaldehyde inhibits the oxidation of all-trans retinal to all-trans retinoic acid by ALDH1A1, but not the differentiation of HL-60 promyelocytic leukemia cells exposed to all-trans retinal.

Authors:  James Russo; Annette Barnes; Katie Berger; Jay Desgrosellier; Jennifer Henderson; Ana Kanters; Lubo Merkov
Journal:  BMC Pharmacol       Date:  2002-02-12

7.  ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells.

Authors:  Jan S Moreb; Henry V Baker; Lung-Ji Chang; Maria Amaya; M Cecilia Lopez; Blanca Ostmark; Wayne Chou
Journal:  Mol Cancer       Date:  2008-11-24       Impact factor: 27.401

8.  Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.

Authors:  Martin P Barr; Steven G Gray; Andreas C Hoffmann; Ralf A Hilger; Juergen Thomale; John D O'Flaherty; Dean A Fennell; Derek Richard; John J O'Leary; Kenneth J O'Byrne
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

9.  ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome.

Authors:  Ting Li; Yun Su; Yuping Mei; Qixin Leng; Bingjie Leng; Zhenqiu Liu; Sanford A Stass; Feng Jiang
Journal:  Lab Invest       Date:  2009-12-14       Impact factor: 5.662

10.  Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.

Authors:  Qinghua You; Huanchen Guo; Dongxiang Xu
Journal:  Drug Des Devel Ther       Date:  2015-09-03       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.